China’s large-cap pharmaceutical groups have been actively scouting for overseas M&A deals in recent years, with the aims of acquiring advanced technology and bigger global market shares. These cash-rich players’ interest in outbound investment is set to remain high, experts predict.
SHANGHAI – As they seek to acquire new technology, bolster R&D pipelines and expand overseas, major Chinese pharma firms are seen as continuing on an international acquisitive streak.
“The trend of outbound investment is definitely up,” Helen Chen, director and partner at L.E.K. Consulting, told PharmAsia News. “We...
Create an account to read this article
Already a subscriber?
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.
BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.
Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.
Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.
